A new survey by Willis Towers Watson suggests that some employers are seeking drug spending relief in biosimilars, according to a Center for Biosimilars report.
Thirty percent of the surveyed employers, according to the report, plan to leverage biosimilars when possible, with 39 percent with plans to take action in the next two years.
“In a full-employment economy, employers feel the pressure to offer competitive benefits and can’t compromise on employee affordability,” Willis Towers Watson’s Julie Stone said in a statement. “With employers and employees seeing no end in sight, many companies are getting creative and tapping into overlooked strategies to shrink the total bill.”
To read the full report by the Center for Biosimilars, click here.